Article Text

Download PDFPDF

5PSQ-040 Real-life direct-acting antivirals effectiveness comparative study in HIV-hepatitis C virus coinfected patients
  1. L Margusino-Framiñan1,
  2. C Mondelo-Garcia1,
  3. V Gimenez-Arufe1,
  4. N Fernandez-Bargiela1,
  5. C Fernandez-Oliveira1,
  6. S Rotea-Salvo1,
  7. P Cid-Silva1,
  8. A Mena-de-Cea2,
  9. I Rodriguez-Osorio2,
  10. I Martin-Herranz1,
  11. A Castro-Iglesias2
  1. 1Complexo Hospitalario Universitario A Coruña, Pharmacy, A Coruña, Spain
  2. 2Complexo Hospitalario Universitario A Coruña, Infectious Diseases, A Coruña, Spain


Background Chronic hepatitis C (CHC) treatment has dramatically changed with the introduction of direct-acting antivirals (DAAs) for hepatitis C virus (HCV)-infected patients. Available data from clinical trials reveal the effectiveness and safety of DAA, both in mono- or HIV-coinfected patients, with virologic response rates between 92%–98%.

Purpose To compare the real-life effectiveness of DAAs therapy in HCV-monoinfected or HIV-coinfected patients.

Material and methods Prospective study in patients with CHC who initiated treatment for 8–24 weeks, between 1 April 2015 and 1 January 2018. Exclusion criteria: patients from penitentiary centres and paediatric patients. Main variable: sustained virological response 12 weeks’ post-treatment (SVR12). Covariates: gender, age, HIV coinfection, previous treatment, hepatic transplantation, cirrhosis, fibrosis, viral genotype, baseline viral load and antiviral treatment. Statistical method: descriptive analysis comparing patients with SVR and patients with relapse. Statistical significance was calculated with the Fisher exact test and the Mann–Whitney U test. This study was authorised by the Health System Investigation Committee.

Results One-thousand three-hundred and thirteen patients were included. One-thousand one-hundred and forty-one monoinfected, 172 HIV-coinfected: 73% males; 49.2 years mean age; 66.2% genotype 1; 23.8% cirrhotics (F4), 20.1% F3 fibrosis grade, 34.3% F2. 2.3% with hepatocellular carcinoma; 22.6% HCV-treatment-experienced; 31.6% null-responders and 23.7% recidivists to previous treatments; 90.9% with estimated glomerular filtration rate ≥60 mL/min; 58.8% treated with ledispasvir/sofosbuvir±ribavirin, 19.2% with sofosbuvir/daclatasvir±ribavirin and 7.0% with sofosbuvir/velpatasvir; and 79.1% treatment length for 12 weeks, 15.1% for 24 weeks and 5.2% for 8 weeks. There were no clinical or statistical critical basal differences related with DDAs’ effectiveness in genotype, fibrosis grade or treatment experience between mono- or HIV-coinfected patients (p>0.05). Effectiveness results: HIV-coinfected vs monocoinfected patients: 0.6% vs 1.3% recidivists (p=0.66); 0.6% vs 0.3% null-responders (p=0.97); and 93.6% vs 96.6% SVR12 (p=0.091).

Conclusion DAAs against HCV are highly effective in HIV-coinfected patients, with response rates very similar to those observed in clinical trials. Also, no effectiveness differences were observed compared with HCV-monoinfected patients, even in this studied population with a high presence of advanced fibrosis grade. So, HIV-coinfection cannot constitute a barrier to accessibility to chronic hepatitis C interferon-free treatments for HCV/HIV-coinfected patients.

References and/or acknowledgements Milazzo L, et al. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy. HIV Med 2017;18:284–91.

No conflict of interest.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.